Fangli Pei

No ORCID on file · 13 papers in corpus · active 2024-2026

Study types

  • article 9
  • other 4

Condition tags

  • endometriosis 13
  • mesh:D004715 2
article 2026
Additional file 1 of Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
·doi:10.6084/m9.figshare.31330008.v1

Supplementary Material 1: 14 herbs of LSNYP.

article 2026
Additional file 1 of Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
·doi:10.6084/m9.figshare.31330008

Supplementary Material 1: 14 herbs of LSNYP.

article 2026
Additional file 2 of Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
·doi:10.6084/m9.figshare.31330011

Supplementary Material 2: 114 Potential active components.

article 2026
Additional file 2 of Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
·doi:10.6084/m9.figshare.31330011.v1

Supplementary Material 2: 114 Potential active components.

article 2026
Additional file 3 of Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
·doi:10.6084/m9.figshare.31330014.v1

Supplementary Material 3: 217 potential therapeutic targets.

article 2026
Additional file 3 of Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
·doi:10.6084/m9.figshare.31330014

Supplementary Material 3: 217 potential therapeutic targets.

article 2026
Additional file 4 of Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
·doi:10.6084/m9.figshare.31330017.v1

Supplementary Material 4: Main quality control components were identified by UHPLC-Q/TOF-MS.

article 2026
Additional file 4 of Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
·doi:10.6084/m9.figshare.31330017

Supplementary Material 4: Main quality control components were identified by UHPLC-Q/TOF-MS.

other 2026
Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
Hereditas ·doi:10.1186/s41065-026-00637-2

BACKGROUND: Luoshi Neiyi prescription (LSNYP) is a traditional Chinese medicine that has a clinical effect on endometriosis (EMs). This study combined network pharmacology with experimental validation to explore its potential molecular mech…

other 2026
Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
·doi:10.6084/m9.figshare.c.8307684.v1

Abstract Background Luoshi Neiyi prescription (LSNYP) is a traditional Chinese medicine that has a clinical effect on endometriosis (EMs). This study combined network pharmacology with experimental validation to explore its potential molecu…

other 2026
Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
·doi:10.6084/m9.figshare.c.8307684

Abstract Background Luoshi Neiyi prescription (LSNYP) is a traditional Chinese medicine that has a clinical effect on endometriosis (EMs). This study combined network pharmacology with experimental validation to explore its potential molecu…

article 2024
Luoshi Neiyi Prescription inhibits estradiol synthesis and inflammation in endometriosis through the HIF1A/EZH2/SF-1 pathway
Journal of ethnopharmacology ·doi:10.1016/j.jep.2024.118659
other 2024
Potential mechanism of Luoshi Neiyi prescription in endometriosis based on serum pharmacochemistry and network pharmacology
Frontiers in pharmacology ·doi:10.3389/fphar.2024.1395160

INTRODUCTION: Endometriosis (EMs) is characterized by ectopic growth of active endometrial tissue outside the uterus. The Luoshi Neiyi prescription (LSNYP) has been extensively used for treating EMs in China. However, data on the active che…